Page 118 — The Frank-Starling curve, congestion, and titrating diuretics & ACE inhibitors in heart failure
Discovered by Otto Frank and Ernest Starling in the early 20th century, the Frank-Starling law describes an intrinsic property of cardiac muscle: within physiological limits, the more the ventricle fills during diastole (preload), the more forcefully it contracts, ejecting a greater stroke volume. This beat-to-beat, autoregulatory mechanism allows the heart to instantly match output to venous return without requiring nervous or hormonal signaling — a purely mechanical safeguard that keeps the two sides of the circulation in balance.
The Frank-Starling relationship arises from the length-tension properties of cardiac sarcomeres. As venous return fills the ventricle during diastole, myocardial fibers stretch, which:
• Increases the overlap between actin and myosin filaments toward an optimal configuration (~2.2 µm sarcomere length) • Increases myofilament calcium sensitivity — stretched sarcomeres bind Ca²⁺ more effectively (part of the "length-dependent activation" phenomenon) • Produces a greater force of contraction on the next systole, without any change in heart rate or contractility (inotropic state)
The curve — stroke volume (or cardiac output) plotted against preload (left-ventricular end-diastolic pressure or volume) — rises steeply at low-to-moderate filling pressures, then flattens into a plateau as sarcomeres approach their optimal stretch and further filling yields diminishing returns.
Beyond the plateau, further increases in preload add little additional stroke volume. If filling continues to rise sharply — as with acute volume overload — sarcomeres can be stretched past their optimal length, and the descending limb of the curve appears: stroke volume actually falls as preload keeps rising. This is uncommon in the intact healthy heart (the pericardium and connective tissue limit overstretch) but becomes clinically relevant in decompensated heart failure, where filling pressures climb into a range that produces both congestion and reduced forward output.
A single Frank-Starling curve is not fixed — it shifts with contractility. Sympathetic stimulation or inotropic drugs shift the whole curve upward and to the left (more output at any given preload); a failing, poorly contractile ventricle shifts it downward and to the right. This shiftability is exactly what the next stages of this simulation explore.
Heart failure does not abolish the Frank-Starling relationship — it degrades it. Reduced contractility (from ischemic injury, cardiomyopathy, chronic pressure/volume overload) means the ventricle generates less stroke volume at any given filling pressure, and the curve becomes flatter overall. Worse, the failing heart typically needs a higher preload just to sustain adequate output, pushing it into filling pressures that produce pulmonary and systemic congestion — the hallmark symptoms of decompensated heart failure.
Two changes define the failing-heart curve relative to the healthy one:
• Downward shift (reduced ceiling): impaired contractility — from lost or dysfunctional myocytes, fibrosis, or chronic overload — means each unit of stretch produces less contractile force. The maximum achievable stroke volume is lower at every preload.
• Rightward shift (need for higher preload): to compensate for reduced contractile efficiency, the failing ventricle "leans on" the Frank-Starling mechanism harder than normal, operating at a higher baseline filling pressure just to maintain acceptable output. This is reinforced by neurohormonal compensation — activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system drives sodium and water retention, raising circulating volume and venous return.
The net effect: the failing heart operates further along its own curve, at pressures which — on a healthy curve — would be entirely unremarkable, but which now cause pulmonary edema, hepatic congestion, and peripheral edema.
Clinicians commonly classify decompensated heart failure along two axes, both readable from where a patient sits on their (shifted) Frank-Starling curve:
• "Wet" (congested): filling pressure is too high — pulmonary and systemic congestion dominate the picture (dyspnea, orthopnea, edema), even though stroke volume may be only modestly reduced.
• "Cold" (hypoperfused): forward stroke volume/cardiac output is too low — fatigue, cool extremities, renal hypoperfusion dominate, sometimes with filling pressures that are not dramatically elevated.
Many decompensated patients are both "wet and cold" — high filling pressure with low output — precisely because the failing curve is both flatter and shifted rightward. This dual problem is why therapy must address both preload (diuretics) and the heart's working conditions (afterload reduction with ACE inhibitors), rather than either alone.
A key clinical insight: because the failing curve is much flatter than the healthy curve, aggressive volume loading buys very little extra stroke volume but produces large increases in filling pressure and congestion. This asymmetry is the physiological rationale for prioritizing decongestion in acute heart failure management.
Diuretics are the cornerstone of symptomatic relief in congested heart failure. By promoting renal sodium and water excretion, they reduce circulating blood volume and, in turn, venous return to the heart. On the Frank-Starling diagram, this appears as the operating point sliding leftward along the failing curve — away from the steep congestion zone and toward filling pressures the compromised heart tolerates without symptoms.
Loop diuretics (furosemide, bumetanide, torsemide) block the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle, producing potent natriuresis and diuresis. The resulting reduction in plasma and extracellular fluid volume lowers venous return and, consequently, ventricular filling pressure (preload).
Crucially, diuretics do not repair the underlying contractile deficit — they do not move the patient onto a better curve, only to a better point on the same (still-depressed) curve. Because the failing curve is flat and shifted, this leftward slide typically produces a large drop in congestive symptoms with only a small, often clinically insignificant, reduction in stroke volume — as long as filling pressure stays above the steep ascending portion of the curve.
The ascending limb of the failing Frank-Starling curve is steep at low preload: below a certain filling pressure, stroke volume falls off quickly as preload continues to drop. Push diuresis too far — from excessive dosing, rapid fluid removal, or superimposed dehydration (vomiting, poor oral intake, hot weather) — and the patient slides down the steep part of the curve into inadequate filling: reduced stroke volume, hypotension, prerenal azotemia, and worsening fatigue that can be mistaken for undertreated heart failure.
This is why diuretic titration in clinical practice tracks weight, renal function (creatinine/BUN), blood pressure, and symptoms together — not congestion alone. The goal is the flattest, most comfortable point on the curve, not the lowest possible preload.
"Diuretic resistance" — declining response to escalating doses — commonly develops in chronic heart failure as the kidney adapts (distal nephron hypertrophy, reduced diuretic delivery from lower renal blood flow). Sequential nephron blockade (adding a thiazide) or switching to a more potent loop diuretic are typical uptitration strategies once standard dosing plateaus.
Where diuretics act on the x-axis of the Frank-Starling diagram (preload), ACE inhibitors improve the curve itself. By blocking the conversion of angiotensin I to angiotensin II, ACE inhibitors reduce angiotensin II-mediated arterial vasoconstriction — lowering afterload, the resistance the failing ventricle must eject against — while their longer-term neurohormonal effects slow the maladaptive cardiac remodeling that otherwise drives progressive decline in contractile function.
Angiotensin II is a potent vasoconstrictor acting on arterial smooth muscle via AT1 receptors, raising systemic vascular resistance (afterload). For a failing ventricle already struggling to generate adequate contractile force, high afterload compounds the problem: more resistance to eject against means less of the heart's limited contractile energy translates into forward stroke volume.
By inhibiting ACE, angiotensin II generation falls, arterial tone relaxes, and afterload decreases. On the Frank-Starling picture, this behaves as if the curve itself is nudged upward — at the same preload, the ventricle now ejects more effectively because it faces less resistance. This is distinct from (and complementary to) the diuretic effect of moving the operating point along the curve; ACE inhibition changes what the curve can achieve.
Chronic activation of the renin-angiotensin-aldosterone system (RAAS) is not merely a compensatory nuisance — it actively drives the disease process. Angiotensin II and downstream aldosterone promote:
• Myocyte hypertrophy and apoptosis • Interstitial and perivascular fibrosis (stiffening the ventricle, impairing both contraction and relaxation) • Progressive chamber dilation and ejection fraction decline (adverse remodeling) • Sodium and water retention, reinforcing the volume overload diuretics must then correct
By interrupting this loop upstream, ACE inhibitors provide benefit that unfolds over weeks to months, distinct from and additive to their immediate hemodynamic (afterload-reducing) effect. This dual action — acute afterload relief plus long-term anti-remodeling — is why ACE inhibitors (and later, ARNI, beta-blockers, and MRAs) are foundational, disease-modifying therapies in heart failure with reduced ejection fraction, not just symptomatic add-ons.
Landmark trials (CONSENSUS 1987, SOLVD 1991) established that ACE inhibitors reduce mortality in heart failure with reduced ejection fraction — a benefit attributable not just to hemodynamic improvement but to slowing the structural remodeling that drives disease progression. This is why ACE inhibitor therapy is titrated toward target doses even after symptoms improve, not simply until congestion resolves.
Neither diuretics nor ACE inhibitors are dosed to a fixed target for every patient. Titration is an iterative, individualized process: increase diuretic and ACE inhibitor doses to relieve congestion and reduce afterload, while continuously monitoring blood pressure, renal function, and electrolytes to avoid pushing the patient into hypoperfusion or renal injury. The safe zone sits between two failure modes — too little therapy leaves the patient congested; too much leaves them underfilled and hypotensive.
Two patients with the same heart failure diagnosis can require very different doses to reach the same physiological target. Differences in baseline renal function, blood pressure, volume status, concurrent medications, and the severity of the underlying curve shift all change how much diuretic and ACE inhibitor dose is needed — and how much can be tolerated.
The practical approach is stepwise: start low, reassess frequently (symptoms, weight, blood pressure, renal function, electrolytes), and increase incrementally. Diuretic dose is titrated primarily to euvolemia and symptom relief; ACE inhibitor dose is titrated toward the highest tolerated dose (ideally guideline target dose) for its long-term remodeling benefit, independent of whether symptoms have already improved at a lower dose.
Diuretics and ACE inhibitors act on different axes of the same diagram, and their combined, carefully titrated effect is what defines successful heart failure management:
• Diuretics slide the operating point leftward along the (still depressed) curve, out of the congestion zone • ACE inhibitors lift the curve itself upward by reducing afterload, so the same preload now yields more stroke volume, and over months, the curve degrades more slowly (or partially recovers) as remodeling is blunted • Together, a well-titrated patient sits in a "sweet spot": low enough preload to avoid congestion, high enough to maintain adequate filling and renal perfusion, on the best-achievable curve for their degree of underlying disease
Over-titration of either drug class narrows this sweet spot from the other side — too much diuresis plus too much afterload reduction can drop both preload and blood pressure simultaneously, producing hypotension and prerenal azotemia even though the "textbook" direction of each therapy was correct.
Clinical teaching sometimes calls this the "diuretic-vasodilator balance": relieving congestion without compromising perfusion. There is no universal target number — the endpoint is a patient who is free of congestive symptoms, hemodynamically stable, and maintained on the highest tolerated guideline-directed medical therapy for long-term outcomes, not just the lowest filling pressure achievable in isolation.